Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Features

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

Michael O'Riordan

October 17, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Conference News ESC 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

Michael O'Riordan

September 01, 2025

News Daily News

Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More

Michael O'Riordan

December 06, 2024

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

L.A. McKeown

October 02, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Opinion CV Team Dispatch

July 2024 Dispatch for the CV Team

L.A. McKeown

July 01, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Caitlin E. Cox

April 15, 2024

News Conference News ESC Heart Failure 2023

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

Shelley Wood

May 25, 2023

News Features

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

Shelley Wood

December 20, 2022

News Daily News

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

Todd Neale

September 15, 2022

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

Mavacamten Successful in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM

Shelley Wood

May 11, 2020

News Daily News

Best-Yet Study of Footballers Raises New Questions Over Preparticipation Cardiac Tests for Athletes

Michael O'Riordan

August 09, 2018

Advertisement

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

CVD Still the Leading Cause of Death and Disease Globally

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

July 2024 Dispatch for the CV Team

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Mavacamten Successful in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM

Best-Yet Study of Footballers Raises New Questions Over Preparticipation Cardiac Tests for Athletes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content